HomeBIOVF • OTCMKTS
add
Swedish Orphan Biovitrum AB (publ)
Previous close
$29.79
Year range
$24.08 - $32.25
Market cap
96.69B SEK
Avg Volume
47.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Financials
Income Statement
Revenue
Net income
| (SEK) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 6.18B | 13.47% |
Operating expense | 3.53B | 0.28% |
Net income | 636.00M | 183.93% |
Net profit margin | 10.30 | 150.00% |
Earnings per share | 2.36 | 227.78% |
EBITDA | 2.14B | 37.10% |
Effective tax rate | 20.15% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.06B | 35.82% |
Total assets | 68.75B | -6.04% |
Total liabilities | 29.68B | -19.38% |
Total equity | 39.07B | — |
Shares outstanding | 344.61M | — |
Price to book | 0.26 | — |
Return on assets | 4.49% | — |
Return on capital | 5.94% | — |
Cash Flow
Net change in cash
| (SEK) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 636.00M | 183.93% |
Cash from operations | 1.45B | -37.83% |
Cash from investing | -424.00M | -863.64% |
Cash from financing | -988.00M | 51.62% |
Net change in cash | 61.00M | -75.79% |
Free cash flow | 888.38M | -60.42% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,937
